HAVCR2 and neoplasm: In addition to using mAbs to block ICPs expression and restore tumor-infiltrating immune cell function, several approaches for targeting LAG-3, TIM-3, and TIGIT via immunotherapy, such as the development of BsAbs, have been reported.